In conclusion, we demonstrated that CAFs are the major regulators of IL-6 in the TME, and blood IL-6 concentration could be a potential biomarker of CAFs, while systemic administration of an anti-IL-6 receptor antibody overcomes CAF-induced immunosuppression and halts tumor progress. Here, IL6 is linked to neoplasm.